CL2021001451A1 - Compuesto macrociclico y su uso - Google Patents

Compuesto macrociclico y su uso

Info

Publication number
CL2021001451A1
CL2021001451A1 CL2021001451A CL2021001451A CL2021001451A1 CL 2021001451 A1 CL2021001451 A1 CL 2021001451A1 CL 2021001451 A CL2021001451 A CL 2021001451A CL 2021001451 A CL2021001451 A CL 2021001451A CL 2021001451 A1 CL2021001451 A1 CL 2021001451A1
Authority
CL
Chile
Prior art keywords
diseases
disease
kidney
mitochondrial
inflammatory
Prior art date
Application number
CL2021001451A
Other languages
English (en)
Inventor
Shigemitsu Matsumoto
Ryoma Hara
Naoyoshi Noguchi
Hideto Fukushi
Ayumu Niida
Satoshi Sasaki
Minoru Ikoma
Toshitake Kobayashi
Tsuyoshi Maekawa
Original Assignee
Scohia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scohia Pharma Inc filed Critical Scohia Pharma Inc
Publication of CL2021001451A1 publication Critical patent/CL2021001451A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un compuesto representado por la fórmula (I): donde cada símbolo es como se lo define en la presente, o una sal de éste, que presenta actividad de activación sobre NRF2, del cual se espera que sea útil como agente preventivo o terapéutico para enfermedades asociadas al estrés oxidativo, particularmente, enfermedades hepáticas (por ejemplo, esteatohepatitis no alcohólica (ENA)), enfermedades cardiovasculares (por ejemplo, insuficiencia cardíaca o hipertensión arterial pulmonar), enfermedades pulmonares (por ejemplo, enfermedad pulmonar obstructiva crónica (EPOC)), enfermedades renales (por ejemplo, enfermedad renal crónica (ERC) o lesión renal aguda (LRA)), enfermedades en el sistema nervioso central (por ejemplo, enfermedad de Parkinson), enfermedades mitocondriales (por ejemplo, ataxia motora de Friedreich o miopatía mitocondrial), enfermedades inflamatorias (por ejemplo, 11 esclerosis múltiple (EM) o enfermedad inflamatoria intestinal (EII)), enfermedades en las células falciformes, cánceres o similares.
CL2021001451A 2018-12-05 2021-06-02 Compuesto macrociclico y su uso CL2021001451A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018228234 2018-12-05

Publications (1)

Publication Number Publication Date
CL2021001451A1 true CL2021001451A1 (es) 2021-12-24

Family

ID=70975488

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001451A CL2021001451A1 (es) 2018-12-05 2021-06-02 Compuesto macrociclico y su uso

Country Status (17)

Country Link
US (1) US11518763B2 (es)
EP (1) EP3890738A4 (es)
JP (1) JP2022510736A (es)
KR (1) KR20210099622A (es)
CN (1) CN113164468A (es)
AR (1) AR117251A1 (es)
AU (1) AU2019391942B2 (es)
BR (1) BR112021010704A2 (es)
CA (1) CA3121952A1 (es)
CL (1) CL2021001451A1 (es)
CO (1) CO2021007304A2 (es)
MX (1) MX2021006527A (es)
PH (1) PH12021551262A1 (es)
SG (1) SG11202105125XA (es)
TW (1) TWI820266B (es)
UA (1) UA127872C2 (es)
WO (1) WO2020116660A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3108534A1 (en) 2018-08-20 2020-02-27 Janssen Pharmaceutica Nv Inhibitors of keap1-nrf2 protein-protein interaction
WO2022056448A1 (en) * 2020-09-14 2022-03-17 Sanofi Tetrahydroisoquinoline derivatives for the treatment of red blood disorders and inflammatory diseases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5946454B2 (ja) 2010-08-31 2016-07-06 バイオニュア ファーマ， エセ．エレ． ニューロトロフィン受容体のアゴニストおよび医薬としてのその使用
RS58581B1 (sr) 2013-06-21 2019-05-31 Karyopharm Therapeutics Inc 1,2,4-triazoli kao modulatori jedarnog transporta i njihova primena
MX370410B (es) * 2013-12-18 2019-12-11 Glaxosmithkline Ip Dev Ltd Reguladores de nrf2.
PL3307739T3 (pl) 2015-06-15 2021-05-31 Glaxosmithkline Intellectual Property Development Limited Regulatory nrf2
EP3307719A1 (en) 2015-06-15 2018-04-18 GlaxoSmithKline Intellectual Property Development Limited Nrf2 regulators
MA52032A (fr) 2015-06-15 2021-01-20 Astex Therapeutics Ltd Régulateurs de nrf2
WO2017026516A1 (ja) 2015-08-12 2017-02-16 持田製薬株式会社 イソチアゾール誘導体
WO2017060855A1 (en) 2015-10-06 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Arylcyclohexyl pyrazoles as nrf2 regulators
EP3359532A1 (en) 2015-10-06 2018-08-15 GlaxoSmithKline Intellectual Property Development Limited Biaryl pyrazoles as nrf2 regulators
JP2020500919A (ja) 2016-12-12 2020-01-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎｒｆ２レギュレーターとしての３−カルボン酸ピロール
EP3551621A1 (en) 2016-12-12 2019-10-16 GlaxoSmithKline Intellectual Property Development Limited N-aryl pyrazoles as nrf2 regulators
WO2018109643A1 (en) 2016-12-14 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Bisaryl heterocycles as nrf2 acti
US11078216B2 (en) 2016-12-14 2021-08-03 Glaxosmithkline Intellectual Property Development Limited Bisaryl amides as NRF2 activators
ES2848699T3 (es) 2016-12-14 2021-08-11 Glaxosmithkline Ip Dev Ltd Compuestos de 3-oxo-1,4-diazepinilo como activadores de NRF2
EP3555082B1 (en) 2016-12-15 2022-01-26 GlaxoSmithKline Intellectual Property Development Limited Ether linked triazoles as nrf2 regulators
CN110114361B (zh) 2016-12-15 2022-04-12 葛兰素史密斯克莱知识产权发展有限公司 Nrf2化合物
AR110590A1 (es) 2016-12-27 2019-04-10 Biogen Ma Inc Activador de nrf2
WO2018140876A1 (en) 2017-01-30 2018-08-02 Biogen Ma Inc. Nrf2 activator
EP3573963B1 (en) 2017-01-30 2021-09-01 Biogen MA Inc. Nrf2 activator
JP2020097526A (ja) * 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物

Also Published As

Publication number Publication date
MX2021006527A (es) 2021-07-21
PH12021551262A1 (en) 2021-10-25
AU2019391942A1 (en) 2021-06-03
TWI820266B (zh) 2023-11-01
BR112021010704A2 (pt) 2021-08-24
EP3890738A4 (en) 2022-08-17
AR117251A1 (es) 2021-07-21
CA3121952A1 (en) 2020-06-11
WO2020116660A1 (en) 2020-06-11
EP3890738A1 (en) 2021-10-13
US11518763B2 (en) 2022-12-06
AU2019391942B2 (en) 2024-03-21
KR20210099622A (ko) 2021-08-12
CN113164468A (zh) 2021-07-23
US20220119391A1 (en) 2022-04-21
JP2022510736A (ja) 2022-01-27
CO2021007304A2 (es) 2021-06-21
UA127872C2 (uk) 2024-01-31
SG11202105125XA (en) 2021-06-29
TW202039494A (zh) 2020-11-01

Similar Documents

Publication Publication Date Title
CL2021001451A1 (es) Compuesto macrociclico y su uso
CO6280490A2 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
BR112016023808A2 (pt) ?veículo?
CR20130524A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
ECSP088628A (es) Moduladores de receptores cannabinoides
CR20130259A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
BR112014003587A2 (pt) derivados de 5-flúor-4-imino-3-(substituído)-3,4-di-hidropirimidin-2(1h)ona
UY31310A1 (es) Ácidos 6-fenilnicotínicos sustituidos y su uso
BR112013002112A2 (pt) composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável ou n-óxido, ou um solvato ou hidrato do mesmo, ou de uma composição
CR20210085A (es) Compuestos de 2,6-diaminopiridina
BR112015017251A8 (pt) composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas
AR085616A1 (es) Composicion farmaceutica inhalable que comprende glicopirrolato, uso
AR090806A1 (es) Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
AR091888A1 (es) Compuestos de urea y su uso como inhibidores de enzimas
BR112014012892A2 (pt) agentes de reversão anticoagulantes
CO6400226A2 (es) Micrólido anti-inflamatorio
CL2013000021A1 (es) Forma cristalina delta de la sal de arginina de perindoprilo; procedimiento de preparacion; composiciones farmaceuticas que la contienen; y su uso par el tratamiento de las enfermedades cardiovasculares, tales como hipertension arterial, insuficiencia cardiaca o enfermedad coronaria estable.
AR084209A1 (es) Metodo para la sintesis de derivados de aminociclohexanona sustituidos
WO2014176510A3 (en) N-(4-(bis(4-(dimethylamino)phenyl)methylene)-8-(dimethylamino) naphthalen-1(4h)-ylidene)-n-methylmethanaminium, derivatives, and their use in treating cancer
Schumacher Arthritis and other Musculoskeletal Features in SLE
Johnson Cardiotoxicity: 2 case reports
ES2446215R2 (es) Aplicación terapéutica de agentes inhibidores de cd44 frente a la leucemia linfoblástica aguda (all) humana.
TH160030A (th) ไตรเทอร์พีนอยด์สังเคราะห์และวิธีการของการใช้ในการบำบัดของโรค
MOHAMMED CHRONIC OBSTRUCTIVE PULMONARY DISEASE AMONG WOMEN USING BIOMAS FUELS IN SOME RURAL AREAS OF FAYOUM GOVERNORATE